Printer Friendly
The Free Library
14,497,195 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Nippon Kayaku Seeking Additional Approval for Its Antitumor Agent.


Tokyo, Japan, July 4, 2006 - (JCN JCN Japan Corporate News
JCN Journal of Cognitive Neuroscience
JCN Journal of Cardiovascular Nursing
JCN Journal of Christian Nursing
JCN Job Control Number
JCN Journal of Child Neurology
JCN joint communications network (US DoD) 
) - Nippon Kayaku has filed an application for its proprietary antitumor agent, Randa Inj. (cisplatin cisplatin /cis·plat·in/ (sis´plat-in) DDP; a platinum coordination complex capable of producing inter- and intrastrand DNA crosslinks; used as an antineoplastic.

cis·plat·in
n.
), for use in combination therapy, with the Ministry of Health, Labor and Welfare.

The company expects to obtain additional approval for the combination therapy of Randa and pemetrexed, which is indicated for the treatment of malignant pleural Pleural
Pleural refers to the pleura or membrane that enfolds the lungs.

Mentioned in: Pneumothorax


pleural

emanating from or pertaining to the pleura.
 mesothelioma Mesothelioma Definition

Mesothelioma is an uncommon disease that causes malignant cancer cells to form within the lining of the chest, abdomen, or around the heart. Its primary cause is believed to be exposure to asbestos.
.

Currently in Japan, the number of people who die from malignant pleural mesothelioma has been increasing. In 2004, 834 people died from the disease.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Jul 4, 2006
Words:92
Previous Article:SPARX Capital Partners Aqcuire NILE'S Communications Shares.
Next Article:Asahi Kasei Pharma, CoTherix Conclude Licensing Agreement for Fasudil, Rho-kinase Inhibitor.



Related Articles
Sartomer. (Contracts, licenses) (Brief Article)
Westchester market parallels Fairfield recovery. (Westchester County, NY)(Focus on: Suburban Markets)(Industry Overview)
Sartomer, Exton, PA, announced that as of September 1 it will operate in Japan on an independent basis under the name Sartomer Japan.(Acquisitions,...
Nippon Kayaku to Merge Two Consolidated Subsidiaries in June.
Shionogi, Nippon Kayaku Receive Approval for Cetrotide.
Novartis Pharma Obtains Additional Approval for Osteoclastic Inhibitor Zometa.
Translational Research Develops Intranasal Formulation of Granisetron, Antiemetic Agent.
Daiichi Sankyo Now Authorized to Market Its Products in China.
Shionogi, Nippon Kayaku to Release Cetrotide.
Nippon Kayaku, Shionogi Release Cetrotide, Premature Ovulation Inhibitor, in Japan.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles